Background Effectual management of bladder malignancies (BMs) is currently a global challenge due to their expensive therapeutic and diagnostic cost burden, together with augmented progression/recurrence rate. Purpose This review aimed to explore cutting-edge diagnostic and therapeutic techniques for meeting the current clinical requirements for effectively managing BMs encompassing dual muscle-invasive bladder tumors (MIBT) and nonmuscle-invasive bladder tumors (NMIBT). Methods A comprehensive review of relevant literature (including data review from 2019 to 2024) was performed to collect valuable information regarding the utilization of advanced diagnostic and therapeutic techniques for the effective management of BMs. Results Studies investigating the potential applications and possible limitations of various methods, including UroVysion, continuous bladder irrigation (CBI), transurethral resection of bladder tumor (TURBT), laparoscopic, and robot-abetted extended pelvic lymph node dissection (PLND), 3D culture models and nerve spring technique (NST) in robotic intracorporeal Studer’s orthotopic neobladder (RISON) have been examined. Similarly, the role of Urothelial Piezo channels (Piezo1 and Piezo2) in urinary system modulation, human epidermal growth factor receptor (HER2)-selective therapy in metastatic urothelial carcinoma (MUC) patients, and diagnostic benefits of fluorescence in situ hybridization (FISH) in BMs have been analyzed. Current report enlisted the major clinical applications associated with the advanced diagnostic and therapeutic techniques with consequent management of lower urinary tract malfunctions (LUTMs), stress urinary incontinence, and BMs, including both MIBT, NMIBT, and MUC. Conclusion This review provided detailed information on numerous benefited outcomes attained from different approaches such as augmented bladder functioning, implementation of collective optical and cancer-specific imaging systems, utilization of tumor-specific biomarkers, precise tumor amputation, reduced urinary complications and hospital stay, postoperative comfort, limited invasiveness, limited blood loss, and ultimately reduced recurrence rates. BMs management at the clinical level needs to be effectively rationalized to enhance the patient’s quality of life and reduce the ultimate cost burden over bladder cancer patients together with appropriate management of associated limitations like urinary tract infections, bladder perforation, bladder infections, and carcinoma relapse in postoperative cases should effectively be encountered to further improve the therapeutic potential of advanced techniques in the near future.
